Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | -0.43% | 688.87 | 2.6% | $679.29m | |
| MRNA | Moderna, Inc. | 0.15% | 118.25 | 0.0% | $616.94m | |
| AMGN | Amgen, Inc. | -1.32% | 225.40 | 1.4% | $605.62m | |
| BIIB | Biogen, Inc. | 1.03% | 267.00 | 1.8% | $554.62m | |
| GILD | Gilead Sciences, Inc. | -2.19% | 61.69 | 1.0% | $514.54m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.11% | 289.54 | 1.9% | $401.56m | |
| ILMN | Illumina, Inc. | -1.56% | 190.79 | 3.2% | $338.76m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 4.40% | 4.27 | 0.7% | $298.49m | |
| SAVA | Cassava Sciences, Inc. | -2.90% | 41.82 | 0.0% | $189.63m | |
| BNTX | BioNTech SE | 0.96% | 134.88 | 0.0% | $112.19m | |
| NVAX | Novavax, Inc. | -1.99% | 18.20 | 75.6% | $84.03m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.34% | 84.77 | 4.2% | $82.56m | |
| NRBO | NeuroBo Pharmaceuticals, Inc. | 9.35% | 13.69 | 0.0% | $78.90m | |
| PRTA | Prothena Corp. Plc | 1.95% | 60.63 | 13.8% | $78.20m | |
| CRSP | CRISPR Therapeutics AG | 1.33% | 65.35 | 0.6% | $76.10m |
Company Profile
Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.